Source:http://linkedlifedata.com/resource/pubmed/id/10621810
Switch to
| Predicate | Object |
|---|---|
| rdf:type | |
| lifeskim:mentions | |
| pubmed:issue |
8
|
| pubmed:dateCreated |
2000-1-13
|
| pubmed:abstractText |
Levomepromazine (previously known as methotrimeprazine) has a broad range of beneficial effects in the terminal phase of many illnesses, resulting from its combined antipsychotic, anxiolytic and sedative actions. Levomepromazine can safely be administered in a continuous subcutaneous infusion with most other commonly used drugs in palliative care.
|
| pubmed:language |
eng
|
| pubmed:journal | |
| pubmed:citationSubset |
IM
|
| pubmed:chemical | |
| pubmed:status |
MEDLINE
|
| pubmed:month |
Aug
|
| pubmed:issn |
1462-3935
|
| pubmed:author | |
| pubmed:issnType |
Print
|
| pubmed:volume |
60
|
| pubmed:owner |
NLM
|
| pubmed:authorsComplete |
Y
|
| pubmed:pagination |
564-7
|
| pubmed:dateRevised |
2006-11-15
|
| pubmed:meshHeading |
pubmed-meshheading:10621810-Antipsychotic Agents,
pubmed-meshheading:10621810-Humans,
pubmed-meshheading:10621810-Methotrimeprazine,
pubmed-meshheading:10621810-Psychomotor Agitation,
pubmed-meshheading:10621810-Psychotic Disorders,
pubmed-meshheading:10621810-Terminal Care,
pubmed-meshheading:10621810-Terminally Ill
|
| pubmed:year |
1999
|
| pubmed:articleTitle |
Levomepromazine (methotrimeprazine) and the last 48 hours.
|
| pubmed:affiliation |
Department of Adult and Elderly Medicine, Countess of Chester Hospital.
|
| pubmed:publicationType |
Journal Article,
Review,
Research Support, Non-U.S. Gov't
|